Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study-Reference-Cited by-同舟云学术

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study

Published:2015-08-25 Issue:3 Volume:142 Page:669-678
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Arpino Grazia,Michelotti Andrea,Truini Mauro,Montemurro Filippo,Russo Stefania,Palumbo Raffaella,Zamagni Claudio,Latorre Agnese,Bruzzese Dario,Riccardi Ferdinando,De Laurentiis Michelino,Beano Alessandra,Biganzoli Laura,Zaniboni Alberto,Laudadio Lucio,Malagoli Maria,Bilancia Domenico,Schettini Francesco,Giuliano Mario,Cazzaniga Marina Elena,De Placido Sabino

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-015-2033-z.pdf

Reference37 articles.

1. Baselga J, Mendelsohn J (1994) Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 64:127–154

2. Baselga J, Norton L, Albanell J et al. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts. Cancer Research 58:2825–2831

3. Baselga J, Cortez H, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119

4. Burstein HJ, Keshaviah A, Baron AD et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110:965–972

5. Chia S, Norris B, Speers C et al (2009) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697–5704

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing treatment for HER2-positive HR-positive breast cancer;Cancer Treatment Reviews;2023-04

2. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study;Cancer Immunology, Immunotherapy;2023-01-10

3. The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making;The Breast;2022-02

4. Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2− Advanced Breast Cancer: A Nationwide Real-World Experience;OncoTargets and Therapy;2021-07

5. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study;ESMO Open;2021-04